Apexigen Inc. (APGN)
Apexigen Statistics
Share Statistics
Apexigen has 24.86M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 24.86M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 22.08M |
| Failed to Deliver (FTD) Shares | 189 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 107.25K, so 0.43% of the outstanding shares have been sold short.
| Short Interest | 107.25K |
| Short % of Shares Out | 0.43% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | 3.8 |
Valuation Ratios
The PE ratio is -0.43 and the forward PE ratio is null. Apexigen's PEG ratio is -0.01.
| PE Ratio | -0.43 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.12 |
| P/FCF Ratio | -0.44 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Apexigen has an Enterprise Value (EV) of -1.2M.
| EV / Sales | 0 |
| EV / EBITDA | 0.04 |
| EV / EBIT | 0.04 |
| EV / FCF | 0.04 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.29 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 52.98 |
Financial Efficiency
Return on Equity is -493.21% and Return on Invested Capital is -494.48%.
| Return on Equity | -493.21% |
| Return on Assets | -137.62% |
| Return on Invested Capital | -494.48% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.86M |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -617K |
| Effective Tax Rate | 1.92% |
Stock Price Statistics
The stock price has increased by 1.3% in the last 52 weeks. The beta is 3.62, so Apexigen's price volatility has been higher than the market average.
| Beta | 3.62 |
| 52-Week Price Change | 1.3% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 44.28 |
| Average Volume (20 Days) | 262.33K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -32.69M |
| Net Income | -31.45M |
| EBITDA | -32.58M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.59 |
Balance Sheet
The company has 14.8M in cash and 106K in debt, giving a net cash position of 14.7M.
| Cash & Cash Equivalents | 14.8M |
| Total Debt | 106K |
| Net Cash | 14.7M |
| Retained Earnings | -176.79M |
| Total Assets | 13.08M |
| Working Capital | -2.81M |
Cash Flow
In the last 12 months, operating cash flow was -30.69M and capital expenditures -57K, giving a free cash flow of -30.75M.
| Operating Cash Flow | -30.69M |
| Capital Expenditures | -57K |
| Free Cash Flow | -30.75M |
| FCF Per Share | -1.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
APGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -233.07% |
| FCF Yield | -227.86% |
Analyst Forecast
Currently there are no analyst rating for APGN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -27.16 |
| Piotroski F-Score | 3 |